Abstract：
:A total of 854 patients with anti-HTLV-I antibody positive ATL, newly diagnosed from 1983 to 1987, were analyzed for prognostic factors. There were 466 males and 388 females with a mean age of 57.1. Of these 269 (31.5%) were alive with a median follow-up time of 14 months from diagnosis, while 585 (65.5%) were dead with a median survival time (MST) of 6 months. MST, and projected 2- and 4-year survival rates of all patients were 10 months, 28% and 12%, respectively. A Cox proportional hazards model analysis revealed that five factors, advanced performance status, high lactic dehydrogenase value, age of 40 years or more, increased number of total involved lesions and hypercalcemia, were associated with shortened survival at P less than 0.01. These factors were used to construct a model to identify patients at three different risks for shortened survival. A group of 178 patients (21.8%) with a hazard ratio of less than 0.5 were classified into the low risk (LR) group, 492 (60.4%) with hazard ratio of less than or equal to 0.5 and less than 2.5 into standard high risk (SHR) group, and 145 (17.8%) with hazard ratio of 2.5 or more extremely high risk (EHR) group. MST, and projected 2- and 4-year survival rates were 37 months, 66.3% and 41.2% for LR, 8 months 20.6%, and 4.5% for SHR, and 2.4 months, 5.6% and 0% for EHR, respectively. The risk grouping is of interest in determining the therapeutic strategy of ATL at diagnosis.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
doi
10.1016/0145-2126(91)90087-asubject
Has Abstractpub_date
1991-01-01 00:00:00pages
81-90issue
2-3eissn
0145-2126issn
1873-5835journal_volume
15pub_type
杂志文章abstract：:Twenty-two patients with myelodysplastic syndromes (MDS) were treated with thalidomide plus arsenic trioxide (ATO). Twenty-two MDS patients receiving supportive care were used as controls. The remission was achieved in 4 patients (18.2%) receiving thalidomide/ATO, and none in the control group (p<0.05). Fifteen of 22 ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2011.12.023
更新日期：2012-06-01 00:00:00
abstract：:It has been suggested that acidic isoferritins play a major role in the regulation of human granulocyte-macrophage (CFU-GM) proliferation. Such regulatory isoferritins are said to occur in some human tissues including both leukaemic and normal leucocytes, and certain established cell lines. They are glycosylated and b...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(84)90065-1
更新日期：1984-01-01 00:00:00
abstract：:The ability of pH-sensitive liposomes and immunoliposomes to deliver synthetic antisense oligonucleotides (oligos) into human myeloid and lymphoid leukaemia cells was examined. The cellular uptake of an 18mer anti-myb oligonucleotide encapsulated in liposomes was from three- to five-fold higher than that of 32P-oligos...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(96)00062-8
更新日期：1996-11-01 00:00:00
abstract：:AG-013736 is an oral anti-angiogenesis agent with activity against a variety of receptor tyrosine kinases, including VEGFR-1, VEGFR-2, VEGFR-3, c-kit, and PDGFR-beta. A phase 2 study was conducted in patients with poor prognosis AML or MDS. Twelve patients (six AML; six MDS) were treated with AG-013736 at a dose of 10...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2005.10.024
更新日期：2006-07-01 00:00:00
abstract：:Up to 30% of patients with acute myeloid leukemia (AML) and abnormal cytogenetics have persistent cytogenetic abnormalities (pCytAbnl) at morphologic complete remission (mCR). We hypothesized that the prognostic significance of pCytAbnl in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) i...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2014.11.007
更新日期：2015-01-01 00:00:00
abstract：:To examine the possibility that ETS family transcription factors, PU.1, SPI-B, ELF-1, ERG-3, ETS-1 and TEL, and homeodomain proteins, HOXA10, HOXC13, MEIS1 and PBX1B, function cooperatively, we investigated their interactions. In luciferase assays, HOXA10 and HOXC13 augmented the activity of PU.1 and SPI-B while dimin...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2008.07.002
更新日期：2009-03-01 00:00:00
abstract：:Myelodysplastic syndromes (MDS) are a group of clonally-acquired blood disorders characterized by ineffective hematopoiesis leading to cytopenias. Red blood cell transfusions are an important component of supportive care in patients with MDS. Prolonged exposure to transfusions can lead to iron overload, which results ...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2017.10.001
更新日期：2017-11-01 00:00:00
abstract：:Hemopoietic responses were studied in splenectomized mice after transplantation of the hemopoietic colony stimulating activity producing leukemia, L8313. In non-splenectomized mice, the number of peripheral leukocytes was elevated to 4 x 10(5)/mm3 after transplantation. In contrast, it was below 1.7 x 10(4)/mm3 in spl...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(89)90159-8
更新日期：1989-01-01 00:00:00
abstract：:To determine the clinical significance of the T helper 1(Th1)/T helper 2 (Th2) ratio in multiple myeloma, the intracellular IFN-gamma and IL-4 were analyzed by flow cytometry in 56 patients with multiple myeloma. The mean Th1/Th2 ratio of cases in the initial diagnosis phase and the refractory phase were higher than t...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.06.003
更新日期：2005-02-01 00:00:00
abstract：:Although abnormalities in granulopoiesis detected by means of bone marrow cytology, culture and kinetic studies have provided prognostic data in preleukemic states and oligoblastic leukemias, this information cannot be applied to individual cases. In order to determine the indications for treatment and the form it sho...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(83)90018-8
更新日期：1983-01-01 00:00:00
abstract：:Imatinib is a tyrosine kinase inhibitor and is now used regularly in chronic myeloid leukaemia therapy in chronic phase with great success. This drug due its very nature of action is suspected to be teratogenic hence the patients are counseled not to get pregnant while on this drug. However in world literature few nor...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2008.03.007
更新日期：2008-10-01 00:00:00
abstract：:The t(8;21)(q22;q22) rearrangement is observed in about 15% of acute myelocitic leukemia (AML) cases, while variant t(8;21) translocations are detected in 6-10% of AML patients positive for the 5'RUNX1/3'CBFA2T1 fusion gene. We report a detailed molecular cytogenetic analysis of a four-way variant t(8;11;16;21)(q22;q1...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.12.018
更新日期：2005-07-01 00:00:00
abstract：:Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for mobilization may aggravate bortezomib-induced polyneuropathy. In t...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.03.015
更新日期：2015-07-01 00:00:00
abstract：:A 53-year-old male patient was admitted to our hospital with painful splenomegaly. He was diagnosed as having chronic myelomonocytic leukemia (CMML) with leukocytosis, monocytosis, increased lysozyme concentrations in serum und urine, and lack of the Philadelphia chromosome. The clinical course of the disease was char...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(96)00117-8
更新日期：1997-03-01 00:00:00
abstract：:We conducted an analysis of the effect of monocytosis at diagnosis of CLL on subsequent overall (OS) and treatment-free survival (TFS). Monocyte counts were performed using the Sysmex XE2100 analyser. A monocyte count >0.9 × 10(9)L(-1) at the time of diagnosis was associated with a shortened OS and TFS. Monocytosis at...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.02.020
更新日期：2013-06-01 00:00:00
abstract：:In vivo infection by HTLV-I is characterized by the lack of virus expression in the host's infected cells and in most cases it is clinically inapparent. The present study shows that exposure of HTLV-I-infected human T-cells to a maximal non-toxic dose of 3-MC remarkably enhances virus expression. This stimulatory effe...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(93)90098-6
更新日期：1993-05-01 00:00:00
abstract：:Chronic lymphocytic leukemia (CLL) is rare in Asians living in Asia and possibly in US Asians. In contrast, CLL is the most common leukemia in whites. The basis for this ethnic and geographic variation is unknown. We compared average annual age-adjusted incidence rates (AAIR) of CLL diagnosed from 1972 to 1995 among L...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(00)00038-2
更新日期：2000-08-01 00:00:00
abstract：:We describe changes in antigen expression on HL60 cells with differentiation into granulocytes induced by all-trans retinoic acid (ATRA) or dimethylsulphoxide (DMSO), into monocytes by alpha1,25-dihydroxyvitamin D3 (D3), or into macrophages by 12-O-tetradecanoyl phorbol-13-acetate (TPA). Undifferentiated cells express...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(98)00041-1
更新日期：1998-06-01 00:00:00
abstract：:FLT3 is a receptor tyrosine kinase involved in the survival of hematopoietic stem cells, and mutations of FLT3 have been reported to be of prognostic significance. This is the first study of FLT3 mutations in pediatric non-promyelocytic AML patients that received the same treatment scheme in single institute. FLT3 int...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.11.006
更新日期：2005-06-01 00:00:00
abstract：:The onset of acute myeloid leukemia following ionizing radiation or alkylating agent exposure is antedated months to years by the development of 'preleukemia', or secondary myelodysplastic syndrome (sMDS). Mitochondrial abnormalities induced by chloramphenicol and clonal deletions of mitochondrial DNA (mt DNA) in the ...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/0145-2126(93)90036-k
更新日期：1993-11-01 00:00:00
abstract：:We studied differentiation inducing effects of retinoic acid (RA), 1 alpha, 25-dihydroxyvitamin D3 (D3) and interferons (IFNs), alone and in combination, on fresh myeloid leukemic cells from 8 patients. RA not only induced the differentiation of leukemic cells in 5/8 cases, but potentiated differentiation by IFNs eith...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90072-h
更新日期：1990-01-01 00:00:00
abstract：:microRNA profiling of acute myeloid leukemia patient samples identified miR-125a as being decreased. Current literature has investigated miR-125a's role in normal hematopoiesis but not within acute myeloid leukemia. Analysis of the upstream region of miR-125a identified several CpG islands. Both precursor and mature m...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.12.021
更新日期：2014-03-01 00:00:00
abstract：OBJECTIVE:Bortezomib-dexamethasone-thalidomide has been reported to be effective in newly-diagnosed multiple myeloma (MM) with an overall response rate of 92% and a CR rate of 18% (Alexanian et al, Hematology 2007;12(3):235-9), but this regimen has not been tested in the Chinese patients. We report here our results tes...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.04.006
更新日期：2009-12-01 00:00:00
abstract：:Adults with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) may be treated either with ongoing systemic chemotherapy or with allogeneic hematopoietic cell transplantation (alloHCT). Despite the presence of phase III trials to support clinical decision-making, we hypothesized that physicians who tr...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2013.10.021
更新日期：2014-02-01 00:00:00
abstract：:The frequency of chromosomal alterations was compared among four children groups: those with Down syndrome and acute leukemia (DS/AL), those with acute leukemia (AL), those with only Down syndrome (DS) and healthy children (NC). The frequency of acquired chromosome abnormalities was larger in the AL group, followed by...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2005.03.015
更新日期：2005-11-01 00:00:00
abstract：:GNAS1 gene is located at the long arm of chromosome 20 (q13.32). GNAS1 gene deletion has never been investigated in MDS. A GNAS1 activating mutation (R201) was recently found in MDS. We applied FISH and DHPLC plus sequencing to investigate GNAS1 gene in MDS cases with and without del(20q) at karyotype. ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2014.03.017
更新日期：2014-07-01 00:00:00
abstract：:Although biological and clinical features differ between B-lineage acute lymphoblastic leukemia (ALL) and T-lineage ALL (T-ALL), there have been few reports that focused on the prognosis for T-ALL in adults, primarily due to its rarity. Here, we studied the long-term outcomes and prognostic factors specific for adult ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.08.004
更新日期：2007-07-01 00:00:00
abstract：:Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2017.08.010
更新日期：2017-10-01 00:00:00
abstract：:Discovering genetic predictors of childhood acute lymphoblastic leukemia (ALL) necessitates the evaluation of novel factors including maternal genetic effects, which are a proxy for the intrauterine environment, and robust epidemiologic study designs. Therefore, we evaluated five maternal and offspring xenobiotic meta...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章,多中心研究
doi：10.1016/j.leukres.2013.01.020
更新日期：2013-05-01 00:00:00
abstract：:Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We st...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2009.07.022
更新日期：2010-04-01 00:00:00
